LIPO
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
Lipella Pharmaceuticals Inc. Common Stock (LIPO) is rated C (2.4/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Revisions (C-).
Quantitative Factor Evaluation • Updated
Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms
Ratings of B- and above are for members.
Register free to see every rating — your first 2 weeks of Premium are on us.
Register — 2 weeks freeUnderlying Financial Metrics
Historical Factor Score Progression
| Date | Value | Growth | Profitability | Momentum | Revisions | Overall |
|---|---|---|---|---|---|---|
| 2026-08-03 | C+ (2.7) | C (2.2) | C (2.5) | C (2.4) | C- (2.0) | C (2.4) |
| 2026-08-02 | C+ (2.7) | C (2.2) | C (2.5) | C (2.4) | C- (1.9) | C (2.3) |
| 2026-07-29 | C+ (2.6) | F (0.7) | D+ (1.6) | F (0.3) | D+ (1.5) | D (1.3) |
| 2025-06-30 | C+ (2.6) | F (0.7) | D (1.5) | F (0.3) | D+ (1.5) | D (1.3) |
| 2025-03-31 | C+ (2.7) | D+ (1.5) | D+ (1.5) | F (0.5) | D+ (1.5) | D+ (1.5) |